Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) signed two CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer on March 26, 2026. One is a commercial site transfer for a currently marketed product; the other expands manufacture to a second delivery system for an ophthalmic commercial product.
Both programs are additive to Lifecore’s late-stage pipeline, mark the company’s fourth commercial site transfer in five months, and are expected to contribute to 2028 commercial revenue pending completion of PPQ and regulatory requirements.
Positive
- Fourth commercial site transfer in five months
- Programs expected to contribute to 2028 commercial revenue
- Expansion to a second delivery system for an ophthalmic product
Negative
- Commercial manufacture contingent on PPQ completion and regulatory approval
- Technical transfer from another CDMO requires successful scale-up and qualification
News Market Reaction – LFCR
On the day this news was published, LFCR declined 7.64%, reflecting a notable negative market reaction. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $138.48M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LFCR gained 4.75% with modest volume while several peers like IRWD (+3.24%) and OGI (+2.22%) were also positive, but scanner data did not flag a coordinated sector momentum move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Commercial site transfer | Positive | +0.8% | New CDMO site transfer for an approved aesthetics product with 2029 growth focus. |
| Mar 16 | Earnings and guidance | Positive | -24.4% | Stronger revenue, margins and EBITDA plus 2026 guidance but stock fell sharply. |
| Mar 10 | Conference participation | Neutral | -1.3% | Participation in a healthcare forum and investor meetings announcement. |
| Mar 09 | Earnings date notice | Neutral | -1.1% | Notification of upcoming financial results release and webcast details. |
| Mar 04 | New CDMO agreement | Positive | -0.6% | New development services pact for DT-001 acne treatment device-drug combo. |
Recent positive commercial and partnership announcements have not consistently translated into strong upside moves, and one upbeat earnings report coincided with a sharp selloff.
Over the past month, Lifecore announced multiple CDMO wins, including commercial site transfers and new development agreements, building a late-stage pipeline aimed at future revenue. Earnings for the period ended Dec 31, 2025 showed higher revenue, improved margins, and solid Adjusted EBITDA, yet the stock dropped sharply. Other news, such as conference participation and the latest aesthetics site transfer, saw only modest price reactions. Today’s additional agreements further extend this theme of commercial traction and long-dated revenue visibility.
Regulatory & Risk Context
An effective Form S-3 shelf registration filed on 2025-09-22 registers up to 20,456,637 common shares for resale by existing holders, including shares issuable upon conversion of Series A Convertible Preferred Stock. No usage has been recorded to date.
Market Pulse Summary
The stock moved -7.6% in the session following this news. A negative reaction despite additional late-stage CDMO wins would fit a pattern where strong operational updates have not always supported the share price, including a 24.39% drop after improved earnings and guidance. Investors may have focused on leverage, preferred equity dynamics, or long lead times before the new programs impact revenue in 2028. The existing but unused S-3 resale shelf for over 20M shares could also weigh on sentiment if dilution concerns resurface.
Key Terms
cdmo technical
process performance qualification technical
AI-generated analysis. Not financial advice.
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product --
-- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System --
-- Fourth Commercial Site Transfer Agreement Win in Five Months --
-- Both Programs are Additive to Lifecore’s High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue --
CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer. This customer is a publicly traded U.S.-based pharmaceutical company that has successfully developed multiple marketed products, and continues to advance a pipeline toward commercialization.
One of the agreements is a commercial site transfer under which Lifecore will manufacture a currently marketed product that, until now, has been produced by another CDMO. While this agreement has been signed with an existing customer, this is a new product to Lifecore. The company will perform technical transfer services including process performance qualification (“PPQ”) batches at commercial scale. Upon successful completion of all regulatory requirements, the agreement calls for Lifecore to initiate commercial manufacture of this product.
The second agreement with the same existing customer provides for the expansion of services. Lifecore currently manufactures this commercial product for the treatment of ophthalmic-related diseases in one format and will now begin to manufacture it in a second delivery system. This additional delivery modality is currently manufactured in Europe.
“On the heels of another commercial site transfer agreement announced earlier this week, we are very pleased to announce the signing of these two new agreements during DCAT week,” said Paul Josephs, chief executive officer of Lifecore. “The commercial site transfer, which is the fourth we’ve signed in the last five months, is a testament to Lifecore’s successful new commercial strategy and our prioritization of such transfer programs, which present a higher probability of approval than earlier stage development programs. We believe this high-value program may start generating meaningful commercial revenue in 2028.
“The expansion agreement is also an exciting win for us, as it reflects Lifecore’s growing status as a partner-of-choice for many of our commercial customers. We believe that our unwavering commitment to customer service, high quality standards, and strong technical expertise are key drivers for those customers that continue to place trust in Lifecore for the manufacture of their most important programs. We are honored to have been selected again by this valued customer. We are also very excited by the momentum in our growing late-stage pipeline and remain highly focused on leveraging this success into additional wins in the near future.”
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “aim,” “designed to,” “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our expectation for the referenced programs to contribute to 2028 commercial revenue; Lifecore’s growing status as a partner-of-choice for many of our commercial customers; key drivers for those customers that continue to place trust in Lifecore; the momentum in our growing late-stage pipeline; and our expectations for additional wins in the near future, are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors as, among others, the timing and amount of future expenses, revenue, net income (loss), Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; our ability to maintain or expand our relationships with our current customers, including the impact of changes in consumer demand for the products we manufacture for our customers; our ability to grow and diversify our business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals or for other reasons; our ability to comply with covenants under our credit agreements and to pay required interest and principal payments when due; our ability to fund any redemptions of shares of the outstanding Series A Convertible Preferred Stock if requested by holders in accordance with their terms; our ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on our operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of our third-party suppliers; pharmaceutical industry market forces that may impact our customers’ success and continued demand for the products we produce for those customers; our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-KT for the transition period ended December 31, 2025 (the “December 2025 10-KT”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the SEC, including the risk factors contained in the December 2025 10-KT. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Lifecore Biomedical, Inc. Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors and Media)
415-675-7401
sdiaz@vidasp.com
Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com
FAQ
What did Lifecore (LFCR) announce on March 26, 2026 about new CDMO agreements?
Will the March 26, 2026 agreements increase Lifecore (LFCR) revenue in 2028?
What does the commercial site transfer announced by Lifecore (LFCR) involve?
How does the expansion agreement affect Lifecore’s manufacturing scope for ophthalmic products?
Why is the March 26, 2026 announcement significant for Lifecore (LFCR)’s pipeline?
